Filtered By:
Condition: Thrombosis
Drug: Activase

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 351 results found since Jan 2013.

Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke
AbstractPurpose of ReviewTo review the current evidence and ongoing clinical trials evaluating the efficacy and safety of tenecteplase (TNK), an alternative tissue plasminogen activator (tPA), in the acute management of arterial ischemic stroke (AIS). To date, alteplase is the only tPA approved by the United States FDA for use in AIS.Recent FindingsThere have been multiple phase two and three trials investigating the safety and efficacy of TNK in AIS. In patients with AIS due to large vessel occlusion, one randomized controlled trial demonstrated superiority of TNK for vessel recanalization rates and long-term functional o...
Source: Current Treatment Options in Cardiovascular Medicine - January 2, 2023 Category: Cardiology Source Type: research

Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
Conclusion: This present study observed no difference in the efficacy and safety between biosimilar TNK and rTPA. Our findings are in concordance with published trials showing equivalence between the two molecules.
Source: Annals of Indian Academy of Neurology - January 25, 2023 Category: Neurology Authors: Ayush Mohan Snigdha Komakula Suhas Murali Pooja Anand Dyuti Shah VY Vishnu Awadh Kishor Pandit Ayush Agarwal Deepti Vibha Mamta Bhushan Singh MV Padma Srivastava Rohit Bhatia Source Type: research

Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study
CONCLUSION: This present study observed no difference in the efficacy and safety between biosimilar TNK and rTPA. Our findings are in concordance with published trials showing equivalence between the two molecules.PMID:37034051 | PMC:PMC10081554 | DOI:10.4103/aian.aian_754_22
Source: Atherosclerosis - April 10, 2023 Category: Cardiology Authors: Ayush Mohan Snigdha Komakula Suhas Murali Pooja Anand Dyuti Shah V Y Vishnu Awadh Kishor Pandit Ayush Agarwal Deepti Vibha Mamta Bhushan Singh M V Padma Srivastava Rohit Bhatia Source Type: research

Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research

Tenecteplase a First-Line Thrombolytic for LVO Stroke? Tenecteplase a First-Line Thrombolytic for LVO Stroke?
Tenecteplase confers similar reperfusion, safety, and functional outcomes as alteplase in patients with large-vessel occlusion stroke, new research shows.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - July 12, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Review Non-pharmacological strategies for the treatment of acute ischaemic stroke
Early recanalisation and an increase in collateral blood supply are predictors of favourable outcome in acute ischaemic stroke. Since individual responses to intravenous treatment with alteplase are heterogeneous, additional intra-arterial thrombolytic and mechanical endovascular treatment is increasingly given. Despite encouraging findings from single-centre studies, data from randomised clinical trials have not proven the hypothesis that interventional recanalisation leads to a better outcome. Advanced thrombectomy devices, the effect of ultrasound-enhanced thrombolysis, and imaging-guided selection of patients outside t...
Source: Lancet Neurology - May 24, 2013 Category: Neurology Authors: Michael G Hennerici, Rolf Kern, Kristina Szabo Tags: Review Source Type: research

Clinical Trials in Acute Ischemic Stroke
Abstract Acute ischemic stroke (AIS) is a major cause of mortality and disability and remains a serious and significant global health problem. The development of neurovascular protectants to treat AIS successfully has been beset by disappointments and setbacks. Many promising candidates have lacked significant pleiotropic protective activity for brain tissue and cerebral blood vessels in clinical trials, while those with protective activity have had poor bioavailability or high toxicity. Moreover, the majority of agents did not confer significant neurovascular protection or clinical efficacy, as measured by standa...
Source: CNS Drugs - August 27, 2014 Category: Neurology Source Type: research

Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model
Publication date: Available online 30 March 2016 Source:Pharmacological Research Author(s): Yinzhong Ma, Li Li, Ziran Niu, Junke Song, Yihuang Lin, Huifang Zhang, Guanhua Du The treatment of acute ischemic stroke (AIS) using thrombolysis with recombinant tissue-plasminogen activator (rtPA, alteplase) is limited by its narrow time window and the risk of hemorrhage. Recombinant plasminogen activator (rPA, reteplase) has been used clinically on coronary artery thrombosis and acute myocardial infarction. It is necessary to induce strokes experimentally as a means of validating the rPA timing on patients with AIS. Howe...
Source: Pharmacological Research - March 30, 2016 Category: Drugs & Pharmacology Source Type: research